Wegovy can reduce heart failure symptoms in obese patients, study shows
Novo Nordisk is eyeing the cardiology treatment space for its highly sought-after drug that is dominating the weight loss and diabetes drug landscape.
28 August 2023
28 August 2023
Novo Nordisk is eyeing the cardiology treatment space for its highly sought-after drug that is dominating the weight loss and diabetes drug landscape.
The Sandoz biosimilar, Tyruko, was approved by the US FDA for all indications of Tysabri based on Phase I and III data.
Global sales for Elrexfio are expected to reach $600m by 2029 according to GlobalData's forecast.
The latest fundraise will close in 2024, with plans for one Phase II trial to start by mid-2024.
Soliris is already approved to treat refractory generalised myasthenia gravis in adults in different regions.
The label has been updated to reflect that no dose adjustment is required in all stages of liver disease.
Outsourcing in Clinical Trials Southern California Conference 2023 will be returning to Hyatt Regency La Jolla at Aventine, USA on the 26th-27th September 2023! Focusing on interactive discussions to provide insight into the current major operational issues with running clinical trials in the coming years.
There are currently 13 authorized/approved COVID-19 vaccines in the 7 major pharma markets. Currently, vaccine developers plan to launch updated boosters prior to the upcoming 2023 fall season to target the latest dominant strain, Omicron XBB.1.5. Per GlobalData analysis, mRNA vaccines will likely continue to dominate the market, though as the pandemic winds down, the global COVID-19 vaccines market is expected to decline.
Give your business an edge with our leading industry insights.